BTIG Maintains Their Buy Rating on MacroGenics (MGNX)


BTIG analyst Dane Leone maintained a Buy rating on MacroGenics (NASDAQ: MGNX) today and set a price target of $30. The company’s shares closed on Friday at $21.51.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.9% and a 66.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Blueprint Medicines, and G1 Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MacroGenics with a $34 average price target.

See today’s analyst top recommended stocks >>

Based on MacroGenics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.24 million. In comparison, last year the company had a GAAP net loss of $40.65 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts